We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Here's Why You Should Invest in Alpine (ALPN) Stock Now
Read MoreHide Full Article
Seattle, WA-based Alpine Immune Sciences (ALPN - Free Report) has a diverse pipeline of clinical and preclinical candidates. Its lead pipeline candidate is povetacicept, which is being developed for multiple autoimmune diseases, such as systemic lupus erythematosus, autoimmune glomerulonephritis and autoimmune cytopenias.
Povetacicept is a dual inhibitor of two cytokines, BAFF (B cell activating factor) and APRIL (a proliferation-inducing ligand). BAFF and APRIL cytokines are said to play crucial roles in the pathogenesis of various autoimmune diseases. Alpine believes that povetacicept has the potential to show increased potency compared to wild-type TACI-based compounds and other inhibitors that target BAFF and/or APRIL cytokines individually. In preclinical studies, povetacicept has demonstrated superior efficacy compared to existing therapies or wild-type TACI (transmembrane activator and CAML interactor) - based agents.
Key ongoing clinical studies are the RUBY-4 study, a phase Ib open-label study of povetacicept in autoimmune cytopenias and RUBY-3, phase Ib/IIa, an open-label study of povetacicept in autoimmune glomerulonephritis.
Alpine achieved several important milestones in the development of povetacicept in the first half of the year, including initiating patient enrollment in the RUBY-4 study. Last month, it initiated the second IgA nephropathy (IgAN) dose cohort in the RUBY-3 study. Initial data from the RUBY-3 study is expected later this year and could be an important catalyst for the stock.
Alpine plans to begin a broad and accelerated development program for povetacicept across multiple indications in 2024.
The company currently carries a Zacks Rank #2 (Buy). Alpine’s stock has gained 71.1% so far this year against a decrease of 4.9% for the industry.
Image Source: Zacks Investment Research
In the past 60 days, estimates for Alpine’s 2023 loss per share have narrowed from $1.43 to $1.18 while those for 2024 have improved from a loss of $1.73 to $1.47 per share.
In the past 60 days, the loss per share estimate for Aurinia Pharmaceuticals for 2023 has narrowed from 71 cents per share to 58 cents per share while that for 2024 has narrowed from 43 cents to 28 cents. Year to date, shares of the company have gained 94.7%.
Earnings of Aurinia Pharmaceuticals beat estimates in all the last four quarters, delivering an earnings surprise of 45.61% on average.
In the past 60 days, estimates for KalVista Pharmaceuticals’ 2023 loss per share have narrowed from $3.03 to $2.83 while those for 2024 have improved from a loss of $2.48 to $2.36. Shares of the company have gained 45% year to date.
Earnings of KalVista Pharmaceuticals beat estimates in all the last four quarters, delivering an earnings surprise of 15.82% on average.
In the past 60 days, the Zacks Consensus Estimate for Corcept’s earnings has gone up from 62 cents per share to 78 cents for 2023. The bottom-line estimate has also improved from 61 cents to 83 cents for 2024 during the same time frame. Shares of the company have rallied 59.2% year to date.
CORT’s earnings beat estimates in two of the trailing four quarters and missed the mark in the other two, delivering an average surprise of 6.99%.
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
Here's Why You Should Invest in Alpine (ALPN) Stock Now
Seattle, WA-based Alpine Immune Sciences (ALPN - Free Report) has a diverse pipeline of clinical and preclinical candidates. Its lead pipeline candidate is povetacicept, which is being developed for multiple autoimmune diseases, such as systemic lupus erythematosus, autoimmune glomerulonephritis and autoimmune cytopenias.
Povetacicept is a dual inhibitor of two cytokines, BAFF (B cell activating factor) and APRIL (a proliferation-inducing ligand). BAFF and APRIL cytokines are said to play crucial roles in the pathogenesis of various autoimmune diseases. Alpine believes that povetacicept has the potential to show increased potency compared to wild-type TACI-based compounds and other inhibitors that target BAFF and/or APRIL cytokines individually. In preclinical studies, povetacicept has demonstrated superior efficacy compared to existing therapies or wild-type TACI (transmembrane activator and CAML interactor) - based agents.
Key ongoing clinical studies are the RUBY-4 study, a phase Ib open-label study of povetacicept in autoimmune cytopenias and RUBY-3, phase Ib/IIa, an open-label study of povetacicept in autoimmune glomerulonephritis.
Alpine achieved several important milestones in the development of povetacicept in the first half of the year, including initiating patient enrollment in the RUBY-4 study. Last month, it initiated the second IgA nephropathy (IgAN) dose cohort in the RUBY-3 study. Initial data from the RUBY-3 study is expected later this year and could be an important catalyst for the stock.
Alpine plans to begin a broad and accelerated development program for povetacicept across multiple indications in 2024.
The company currently carries a Zacks Rank #2 (Buy). Alpine’s stock has gained 71.1% so far this year against a decrease of 4.9% for the industry.
Image Source: Zacks Investment Research
In the past 60 days, estimates for Alpine’s 2023 loss per share have narrowed from $1.43 to $1.18 while those for 2024 have improved from a loss of $1.73 to $1.47 per share.
Alpine Immune Sciences, Inc. Price and Consensus
Alpine Immune Sciences, Inc. price-consensus-chart | Alpine Immune Sciences, Inc. Quote
Other Stocks to Consider
Some other top-ranked drug companies worth considering are Aurinia Pharmaceuticals (AUPH - Free Report) , KalVista Pharmaceuticals (KALV - Free Report) and Corcept Therapeutics (CORT - Free Report) , each carrying a Zacks Rank #2 at present. You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.
In the past 60 days, the loss per share estimate for Aurinia Pharmaceuticals for 2023 has narrowed from 71 cents per share to 58 cents per share while that for 2024 has narrowed from 43 cents to 28 cents. Year to date, shares of the company have gained 94.7%.
Earnings of Aurinia Pharmaceuticals beat estimates in all the last four quarters, delivering an earnings surprise of 45.61% on average.
In the past 60 days, estimates for KalVista Pharmaceuticals’ 2023 loss per share have narrowed from $3.03 to $2.83 while those for 2024 have improved from a loss of $2.48 to $2.36. Shares of the company have gained 45% year to date.
Earnings of KalVista Pharmaceuticals beat estimates in all the last four quarters, delivering an earnings surprise of 15.82% on average.
In the past 60 days, the Zacks Consensus Estimate for Corcept’s earnings has gone up from 62 cents per share to 78 cents for 2023. The bottom-line estimate has also improved from 61 cents to 83 cents for 2024 during the same time frame. Shares of the company have rallied 59.2% year to date.
CORT’s earnings beat estimates in two of the trailing four quarters and missed the mark in the other two, delivering an average surprise of 6.99%.